Patent intelligence · US
US 12239677
Therapeutic bacteriophage compositions for treating Staphylococcus infection
Therapeutic bacteriophage compositions for treating Staphylococcus infection
Patent details — US 12239677
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 4, 2025
- Expiration
- Feb 27, 2045
- Applicant
- Armata Pharmaceuticals, Inc.
- Claims
- 28
- CPC classes
- A61K, A61K2300/00, A61K31/395, A61K31/43
Quick answer
US 12239677 (Therapeutic bacteriophage compositions for treating Staphylococcus infection) is held by Armata Pharmaceuticals, Inc.. Status: granted. Granted Mar 4, 2025. Expires Feb 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Armata Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K2300/00, A61K31/395, A61K31/43, A61K31/47, A61K31/545
More from Armata Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12268720
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
granted -
US 11654166
Therapeutic bacteriophage compositions for treating Staphylococcus infection
granted -
US 11253557
Therapeutic bacteriophage compositions
granted -
US 10517908
Therapeutic bacteriophage compositions
granted
Frequently asked questions
What is US patent 12239677?
US 12239677 (Therapeutic bacteriophage compositions for treating Staphylococcus infection) is held by Armata Pharmaceuticals, Inc.. Status: granted. Granted Mar 4, 2025. Expires Feb 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12239677?
Armata Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 12239677 expire?
Our index shows an expiration date of Feb 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.